Deutsche Bank's research report on Aegerion Pharmaceuticals provides an update following discussions with the company's management. The report highlights an increase in SG&A expenses for 2014, reflecting the company's strategy to invest in sales and marketing. The company aims to become profitable in the second half of 2014. The report also discusses the company's focus on customer care, reimbursement negotiations in the EU, and an increase in stock-based compensation due to a rise in stock price. The report reiterates a 'Buy' rating with a price target of $115.
doj/DataSet10/EFTA01450732.pdf
{"title":"Deutsche Bank Markets Research - Aegerion Alert","key_people":["Robyn Kamauskas","Alethia Young"],"document_date":"2013-11-18","document_type":"financial","key_locations":["United States","EU"],"document_subtype":"Research Report","key_organizations":["Deutsche Bank","Aegerion Pharmaceuticals"],"reference_numbers":["DB-SDNY-0106558","SDNY_GM_00252742","EFTA01450732"]}